cerca CERCA
Mercoledì 16 Giugno 2021
Aggiornato: 18:53
Temi caldi

Salute_E_Benessere Salute_E_Benessere Chimica_E_Farmacia Economia_E_Finanza

Associates of Cape Cod, Inc. announces launch of PyroSmart NextGen™ Recombinant LAL Reagent

EAST FALMOUTH, Mass., April 23, 2021 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC), a Seikagaku Group Company, announces the launch of a new, innovative, sustainable recombinant LAL reagent, PyroSmart NextGen™ for Bacterial Endotoxin Testing (BET). The new LAL reagent is sustainably produced using recombinant technology; it is not based on raw materials from animals, unlike traditional LAL reagents which are manufactured using the blood harvested from horseshoe crabs. After years of research...

Agiomix is selected as the Official Operator for the Egyptian Genome Project

CAIRO, April 19, 2021 /PRNewswire/ -- Egypt has announced its plans to establish a map of the Egyptian human genome and enter the world of precision medicine; the Egyptian President Abdel Fattah El Sisi has been briefed on the development of the project by Prime Minister Mustafa Mabdouli and Minister of Higher Education Khaled Abdel Ghaffar.

SunRock Biopharma and GenScript ProBio Enter into a Collaboration Agreement to Develop Novel Monoclonal Antibody Program

NANJING, China, Feb. 22, 2021 /PRNewswire/ -- On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning preclinical discovery to large scale GMP manufacturing for SunRock's CCR9 therapeutic antibody candidates. GenScript ProBio will provide SunRock Biopharma a one-stop-solution from antibody discovery, cell line development, process development to GMP drug substance and drug prod...

Caliber Ophthalmics Opens New State-of-the-Art Ophthalmology Center of Excellence

SINKING SPRING, Pa., Jan. 13, 2021 /PRNewswire/ -- Caliber Ophthalmics, a Surgical Specialties Corporation company, is pleased to announce the opening of a state of the art ophthalmology design and manufacturing Center of Excellence in Sinking Spring, PA. The newly renovated 23,000 square foot facility has a clean room for precision manufacturing of medical devices, an engineering design center, and advanced blade manufacturing capabilities. The site combines the two exceptional teams with decade...

Il test COVID-19/FluA,B/RSV di Seegene con funzione senza estrazione è ora disponibile in Europa

SEOUL, Corea del Sud, 8 dicembre 2020 /PRNewswire/ -- Seegene Inc. (KQ096530), azienda di biotecnologia della Corea del Sud specializzata in diagnostica molecolare, ha dichiarato giovedì che l'applicazione senza estrazione del test SARS-CoV-2/FluA/FluB/RSV Allplex™ è ora disponibile in Europa. In precedenza, a settembre, Seegene aveva introdotto la marcatura CE-IVD per questo prodotto, in vista dell'inizio delle vendite in Europa a partire da ottobre.

Seegene's COVID-19/FluA,B/RSV test with extraction-free feature now available in Europe

SEOUL, South Korea, Dec. 3, 2020 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Thursday that the extraction-free application of Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is now available in Europe. Previously in September, Seegene had CE-IVD marked this product with the sales starting in October in Europe.

INSIGHTEC Announces MR-guided Focused Ultrasound to Treat Essential Tremor Received Funding by National Health Service (NHS) England

HAIFA, Israel and MIAMI, Nov. 24, 2020 /PRNewswire/ -- INSIGHTEC®, a global healthcare company focused on the therapeutic power of acoustic energy, today announced that the National Health Service (NHS) England has approved funding for MR-guided Focused Ultrasound for the treatment of medication-refractory Essential Tremor patients from April 2021. The NHS England is the publicly funded healthcare system for England.

Support reaching out both physicians and the community: SonoScape in Germany

SHENZHEN, China, Oct. 30, 2020 /PRNewswire/ -- With the return from summer break, the continuation of COVID-Exit is much more prepared and planned, and elective surgery momentum has resumed. For physicians, safeguarding both patients, as well as themselves, is by far still the priority, especially in the fear of resurgence.

LumiThera riceve notifica di assegnazione di 1,5 milioni di dollari come sovvenzione dal National Eye Institute per il sostegno al trial clinico multicentrico USA per la cura della retinopatia diabetica e dell'edema maculare

SEATTLE, 3 settembre 2020 /PRNewswire/ -- LumiThera Inc., azienda di dispositivi medicali di fase commerciale che realizza il trattamento di fotobiomodulazione (PBM) per disturbi e malattie oculari, ha annunciato oggi di aver ricevuto un grant di fase II di ricerca innovativa piccole imprese (SBIR) dal National Institute of Health (NIH) e dalla divisione del National Eye Institute (NEI).

LumiThera Receives Notice of Award for $1.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Diabetic Retinopathy and Macular Edema

SEATTLE, Sept. 3, 2020 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI).

ora in
Prima pagina
in Evidenza